We also investigated whether amplification status of TOP2A is correlated with specific benefit from conventional-dose anthracycline-based chemotherapy compared to high-dose alkylating chemotherapy in patients with HER2-positive tumours. The gene discussed is TOP2A; the disease is neoplasm.